Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux

Cancer Research

Volumn 65, Issue 2, 2005, Pages 516-525

  Riganti, Chiara ^a   Miraglia, Erica ^a   Viarisio, Daniele ^a   Costamagna, Costanzo ^a   Pescarmona, Gianpiero ^a   Ghigo, Dario ^a,b   Bosia, Amalia ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Biologia e Biochimica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; NITRIC OXIDE;

ANTIBIOTIC RESISTANCE; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL POPULATION; COLON CANCER; DRUG ACCUMULATION; EFFUSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; COLONIC NEOPLASMS; CYCLIC GMP; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HT29 CELLS; HUMANS; ISOENZYMES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; S-NITROSO-N-ACETYLPENICILLAMINE;

EID: 12544258857     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
2. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A 1994;91:3497-504.
3. von Bossanyi P, Diete S, Dietzmann K, Kirches MW, Kirches E. Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol (Berl) 1997;94:605-11.
4. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Causes Control 2003;10:159-65.
5. Lind DS, Kontaridis MI, Edwards PD, Josephs MD, Moldawer LL, Copeland EM III. Nitric oxide contributes to Adriamycin's antitumor effect. J Surg Res 1997;69:283-7.
6. Aldieri E, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D. Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicol Appl Pharmacol 2002;185:85-90.
7. Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta 1999;1411:273-89.
8. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725-8.
9. Wink DA, Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, cytotoxic and cytoprotective mechanism of nitric oxide. Free Radic Biol Med 1998;25:434-56.
10. Magrinat G, Mason SN, Shami PJ, Weinberg JB. Nitric oxide modulation of human leukaemia cell differentiation and gene expression. Blood 1992;80:1880-4.
11. Murphy MP. Nitric oxide and cell death. Biochim Biophys Acta 1999;1411:401-14.
12. Goldstein LJ. MDR1 expression in solid tumours. Eur J Cancer 1996;32:1039-50.
13. Riganti C, Aldieri E, Bergandi L, et al. Crocidolite asbestos inhibits pentose phosphate oxidative pathway and glucose 6-phosphate dehydrogenase activity in human lung epithelial cells. Free Radic Biol Med 2002;32:938-49.
14. Kinnula VL, Aalto K, Raivio KO, Walles S, Linnainmaa K. Cytotoxicity of oxidants and asbestos fibers in cultured human mesothelial cells. Free Radic Biol Med 1994;16:169-76.
15. Ghigo D, Aldieri E, Todde R, et al. Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. J Clin Invest 1998;102:595-605.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem 1987;162:156-9.
17. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicines, doxorubicine and vinblastine. Proc Natl Acad Sci U S A 1987;84:3004-8.
18. Cole SPC, Bhardway G, Gerlack JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer line. Science 1992;258:1650-4.
19. Brouillard F, Tondelier D, Edelman A, Baudouin-Legros M. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer Res 2001;62:1693-8.
20. Felley-Bosco E, Bender FC, Courjault-Gautier F, Bron C, Quest AFG. Caveolin-I down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc Natl Acad Sci U S A 2000;97:14334-9.
21. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35.
22. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998;95:8880-5.
23. Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P, Hofmann F. Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol 1999;135:105-49.
24. Grandi M, Geroni C, Giuliani FC. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer 1986;54:515-8.
25. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32:945-57.
26. Ambdukar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.
27. Cole SPC, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistance MRP-transfected human tumor cells. Cancer Res 1994;54:5902-10.
28. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003;22:7496-511.
29. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-47.
30. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anticancer drugs. Proc Natl Acad Sci U S A 1999;96:6914-9.
31. Molina y Vedia L, McDonald B, Reep B, et al. Nitric-oxide induced S-nitrosylation of glyceraldehyde 3-phosphate dehydrogenase inhibits enzymatic activity and increase endogenous ADP-ribosylation. J Biol Chem 1992;267:24929-32.
32. Brown GC. Nitric oxide and mithocondrial respiration. Biochim Biophys Acta 1999;1411:351-6.
33. Stamler JS. Redox signalling: nitrosylation and related target interactions of nitric oxide. Cell 1994;78:931-6.
34. Stefanelli C, Pignatti C, Tantini B, et al. Nitric oxide can function as either a killer molecule or an antiapoptotic effector in cardiomyocytes. Biochim Biophys Acta 1999;1450:406-13.
35. Zagozdzon R, Giermasz A, Golab J, Stoklosa T, Jalili A, Jakobisiak M. The potential antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. Cancer Lett 1999;147:67-75.
36. Jung JD, Lee JS, Yun SY, et al. Doxorubicin inhibits the production of nitric oxide by colorectal cancer cells. Arch Pharm Res 2002;25:691-6.
37. Breuer W, Slotki IN, Ausiello DA, Cabantchik IZ. Induction of multidrug resistance downregulates the expression of CFTR in colon epithelial cells. Am J Physiol 1993;265:C1711-5.
38. Kunzelmann K, Slotki IN, Klein P, et al. Effects of P-glycoprotein expression on cyclic AMP and volume-activated ion fluxes and conductances in HT-29 colon adenocarcinoma cells. J Cell Physiol 1994;161:393-406.
39. Duesberg P, Stindl R, Hehlmann R. Explaining the high mutation rate of cancer cells to drug and multidrug resistance by chromosome re-assortments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A 2000;97:14295-300.
40. Kolyada AY, Fedtsov A, Madias NE. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension 2001;38:1024-9.
41. Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K. Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J Cardiovasc Pharmacol 2001;38:69-77.
42. Munyappa R, Xu R, Ram JL, Sowers JR. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol 2000;278:H1762-8.
43. Wong WWL, Tan MM, Zhenlei X, Dimitroulakos J, Minden MD, Penn LZ. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001;7:2067-75.
44. Li X, Liu L, Tupper JC, et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002;277:15309-16.
45. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999;5:2223-9.
46. Wang W, Collie-Duguid E, Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett 2002;531:415-20.
47. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001;18:800-6.
48. Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol Med 2003;9:160-7.
49. Di Stasi AM, Mallozzi C, Macchia G, Petrucci TC, Minetti M. Peroxynitrite induces tyrosine nitration and tyrosine phosphorylation of synaptic proteins. J Neurochem 1999;73:727-35.